🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

659 results for “MS” Clear

  1. A Trial to Examine the Effects of MSP-2020 on Brain Activity in Healthy Adults

    Otsuka Beijing Research Institute

    Incomplete Response - Major Depressive Disorder (IR-MDD)

    phase 1 other active

    1 trial

  2. A clinical research study investigating how the body processes the new compound petrelintide in people with kidney problems

    Zealand Pharma A/S

    Weight management

    phase 1 other active

    1 trial

  3. A randomized, Phase 1b, single-center, observer-blind, active-controlled study to evaluate the safety, immunogenicity, and immunological mechanisms of one single administration of TETRALITE influenza vaccine at two dose levels of LiteVax Adjuvant, in healthy participants aged 60 years and older and in healthy participants aged 18 to 50 years.

    Teva Pharma GmbH

    Influenza

    phase 1 other active

    1 trial

  4. A randomized, investigator masked pilot study to establish the experimental conditions and select the criteria to compare topical application of 2 methyl aminolevulinate creams: evaluation of protoporphyrin IX formation in the skin of healthy subjects.

    Substipharm

    None - Healthy subjects

    phase 1 other active

    1 trial

  5. A randomized, single dose, cross-over bioavailability study comparing the drug-drug interaction between telmisartan tablets, indapamide tablets, and amlodipine tablets when co-administered versus the administration of each product alone in three arms to healthy volunteers under fasting conditions.

    s.r.o.

    high blood pressure

    phase 1 other active

    1 trial

  6. A randomized, single dose, cross-over, replicated, open-label bioequivalence study comparing indacaterol/glycopyrronium (85/43mcg inhalation powder hard capsules) (PG341 [Celon Pharma] vs Ultibro Breezhaler [Novartis])

    Lacuna Pharma Pty Ltd

    Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)

    phase 1 other active

    1 trial

  7. A study to evaluate the effects and safety of INCA033989 in participants with myelofibrosis or essential thrombocythemia

    Incyte

    Myeloproliferative Neoplasms

    phase 1 other active

    1 trial

  8. A study to learn about how much emodepside gets absorbed in the blood and how food affects its absorption when given as a new type of tablet to healthy participants

    Bayer AG

    Onchocerciasis (river blindness): is an infectious disease caused by Onchocerca volvulus, a parasitic nematode worm. The disease is contracted through the bite of an infected blackfly of the genus Simulium, which transmits third-stage infective larvae. An estimated 18 million people suffer from onchocerciasis, with 99% cases in 31 African countries, and 187 million people at risk Onchocercal dermatitis is the most common symptom of the disease, but severe visual impairment and blindness are the most severe complication, and onchocerciasis is the world’s second-leading infectious cause of blindness. Programs for the treatment and control of onchocerciasis through mass drug administration of ivermectin have been in place for over 20 years. However, they require patients to be given treatment (ivermectin) at regular intervals for the life of the adult worm (up to 15 years), making implementation extremely difficult in endemic countries. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug., Soil-transmitted helminth infection: Soil-transmitted helminthiasis is caused by one of the three soil-transmitted helminths (STH), Ascaris lumbricoides, Trichuris trichiura and hookworm (Ancylostoma duodenale and Necator americanus). Currently, STH still infects about 1.5 billion people worldwide, mostly in tropical and subtropical regions. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug.

    phase 1 other active

    1 trial

  9. A study to test different doses of obrixtamig (BI 764532) in patients with small cell lung cancer and other neuroendocrine tumours that are positive for DLL3.

    Boehringer Ingelheim

    Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3

    phase 1 other active

    1 trial

  10. A study to test how BI 456906 is taken up in the blood of people with and without kidney problems

    Boehringer Ingelheim

    Renal impairment (mild, moderate and severe), Healthy

    phase 1 other active

    1 trial

  11. A trial comparing how the body absorbs and gets rid of petadeferitrin taken as two different forms in healthy people

    Lacuna Pharma Pty Ltd

    Iron overload from thalassemia, transfusion-dependent myelodysplastic syndromea and haemolysis

    phase 1 other active

    1 trial

  12. APR-246

    Aprea Therapeutics

    Hematologic Neoplasms

    phase 1 small molecule completed

    1 trial

  13. AVE0005 (aflibercept)

    Regeneron UK Limited

    Colorectal Neoplasms

    phase 1 small molecule completed

    1 trial

  14. AVI-4126 Injection (RESTEN-NG®)

    Sarepta Therapeutics

    Neoplasms

    phase 1 small molecule completed

    1 trial

  15. AZD6244

    AstraZeneca

    Neoplasms,

    phase 1 small molecule completed

    1 trial

  16. Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment

    Eli Lilly Co.

    Prostatic Neoplasms

    phase 1 other active

    1 trial

  17. Allogeneic (MSC's) Application to the Burn Wounds

    United Therapeutics Europe Ltd

    Skin Burn Degree Second

    phase 1 mab completed

    1 trial

  18. Allogeneic MSC

    United Therapeutics Europe Ltd

    Mesenchymal Stromal Cells

    phase 1 mab completed

    1 trial

  19. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Tamsulosin Hydrochloride Capsules USP 0.4 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Tamsulosin Hydrochloride extended-release capsules 0.4 mg, Product of Geolab Indústria Farmacêutica S/A, VP. 1B QD.08-B Modules 01 to 08, DAIA - Anápolis – GO, in healthy adult, human male subjects under fasting condition.

    Lacuna Pharma Pty Ltd

    Benign prostatic hyperplasia (BPH)

    phase 1 other active

    1 trial

  20. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Tamsulosin Hydrochloride Capsules USP 0.4 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Tamsulosin Hydrochloride extended-release capsules 0.4 mg, Product of Geolab Indústria Farmacêutica S/A, VP. 1B QD.08-B Modules 01 to 08, DAIA - Anápolis – GO, in healthy adult, human male subjects under fed condition.

    Lacuna Pharma Pty Ltd

    Benign prostatic hyperplasia (BPH)

    phase 1 other active

    1 trial

  21. An open-label, randomized, single-dose, two-period, two-treatment, crossover bioequivalence study with GP-IMP-001 in healthy male volunteers under fasting conditions.

    Lacuna Pharma Pty Ltd

    inteneded for treatment of - active rheumatoid arthritis in adult patients, - polyarthritic forms of severe, active juvenile idiopathic arthritis, when the response to nonsteroidal anti-inflammatory drugs has been inadequate, - severe recalcitrant disabling psoriasis which is not adequately responsive to other forms of therapy and severe psoriatic arthritis in adult patients, - mild-to-moderate Crohn’s disease, either alone or in combination with corticosteroids, in adult patients refractory or intolerant to thiopurines.

    phase 1 other active

    1 trial

  22. Anti-GD2 ADC M3554 in Advanced Solid Tumors

    Merck Sharp and Dohme

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  23. Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

    Merck Sharp and Dohme

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  24. BI 905711

    Boehringer Ingelheim

    Gastrointestinal Neoplasms

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources